Biopharma company Corcept Therapeutics (NASDAQ: CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million. On the other hand, the company’s full-year revenue guidance of $1 billion at the midpoint came in 7.2% above analysts’ estimates. Its GAAP loss of $0.30 per share was significantly below analysts’ consensus estimates.

Is now the time to buy Corcept? Find out by accessing our full research report, it’s free.

Company Overview

Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, Corcept grew its sales at an excellent 22.1% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Corcept’s annualized revenue growth of 21.2% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong.

This quarter, Corcept’s revenue grew by 4.9% year on year to $164.9 million, falling short of Wall Street’s estimates.

Looking ahead, sell-side analysts expect revenue to grow 11.8% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is commendable and indicates the market sees success for its products and services.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Corcept has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 26.2%.

Looking at the trend in its profitability, Corcept’s adjusted operating margin decreased by 38.9 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 25.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

In Q1, Corcept generated an adjusted operating margin profit margin of negative 30.1%, down 46.1 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for Corcept, its EPS declined by 14.6% annually over the last five years while its revenue grew by 22.1%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

We can take a deeper look into Corcept’s earnings to better understand the drivers of its performance. As we mentioned earlier, Corcept’s adjusted operating margin declined by 38.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, Corcept reported EPS of negative $0.30, down from $0.17 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street expects Corcept’s full-year EPS of $0.36 to grow 41.5%.

Key Takeaways from Corcept’s Q1 Results

We were impressed by Corcept’s optimistic full-year revenue guidance, which blew past analysts’ expectations. On the other hand, its revenue missed and its EPS fell short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock traded up 1.7% to $47.44 immediately after reporting.

So do we think Corcept is an attractive buy at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).